Antiphospholipid syndrome and kidney disease

Kidney International

Volumn 91, Issue 1, 2017, Pages 34-44

  Bienaimé, Frank ^a,b   Legendre, Christophe ^a,b   Terzi, Fabiola ^a,b   Canaud, Guillaume ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

antiphospholipid antibodies; mTORC pathway; vasculopathy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA2 GLYCOPROTEIN 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; GLYCOPROTEIN IB ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOLIPID ANTIBODY; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ANTIPHOSPHOLIPID SYNDROME NEPHROPATHY; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOCYTOSIS; FIBRINOLYSIS; HUMAN; INCIDENCE; KIDNEY ARTERY STENOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEINURIA; RENAL ARTERY THROMBOSIS; REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ALLOGRAFT; ANIMAL; COMPLICATION; DIAGNOSTIC IMAGING; HYPERTENSION; IMMUNOLOGY; KIDNEY; KIDNEY DISEASES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PLASMA EXCHANGE; RENAL ARTERY OBSTRUCTION; VASCULARIZATION;

ALLOGRAFTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DISEASE PROGRESSION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; PLASMA EXCHANGE; RENAL ARTERY OBSTRUCTION; THROMBOSIS;

EID: 84996490708     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.06.026     Document Type: Review

References (125)

1. 1 Levine, J.S., Branch, D.W., Rauch, J., The antiphospholipid syndrome. N Engl J Med 346 (2002), 752–763.
2. 2 Hughson, M.D., Nadasdy, T., McCarty, G.A., et al. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis 20 (1992), 150–158.
3. 3 Miyakis, S., Lockshin, M.D., Atsumi, T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
4. 4 Amigo, M.C., Garcia-Torres, R., Robles, M., et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 19 (1992), 1181–1185.
5. 5 Hughson, M.D., McCarty, G.A., Brumback, R.A., Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 26 (1995), 716–724.
6. 6 Domrongkitchaiporn, S., Cameron, E.C., Jetha, N., et al. Renal microangiopathy in the primary antiphospholipid syndrome: a case report with literature review. Nephron 68 (1994), 128–132.
7. 7 Almeshari, K., Alfurayh, O., Akhtar, M., Primary antiphospholipid syndrome and self-limited renal vasculitis during pregnancy: case report and review of the literature. Am J Kidney Dis 24 (1994), 505–508.
8. 8 Nochy, D., Daugas, E., Droz, D., et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10 (1999), 507–518.
9. 9 Daugas, E., Nochy, D., Huong, D.L., et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13 (2002), 42–52.
10. 10 Tektonidou, M.G., Sotsiou, F., Nakopoulou, L., et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50 (2004), 2569–2579.
11. 11 Griffiths, M.H., Papadaki, L., Neild, G.H., The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. QJM 93 (2000), 457–467.
12. 12 Abreu, M.M., Danowski, A., Wahl, D.G., et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 14 (2015), 401–414.
13. 13 Canaud, G., Bienaime, F., Tabarin, F., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371 (2014), 303–312.
14. 14 Hadaya, K., Ferrari-Lacraz, S., Fumeaux, D., et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11 (2011), 2523–2527.
15. 15 Canaud, G., Kamar, N., Anglicheau, D., et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13 (2013), 2179–2185.
16. 16 Ostuni, P.A., Lazzarin, P., Pengo, V., et al. Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis 49 (1990), 184–187.
17. 17 Ames, D.E., Asherson, R.A., Ayres, B., et al. Bilateral adrenal infarction, hypoadrenalism and splinter haemorrhages in the ‘primary’ antiphospholipid syndrome. Br J Rheumatol 31 (1992), 117–120.
18. 18 Poux, J.M., Boudet, R., Lacroix, P., et al. Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Am J Kidney Dis 27 (1996), 721–725.
19. 19 Kim, J.H., Ha, H.K., Yoon, K.H., et al. CT features of abdominal manifestations of primary antiphospholipid syndrome. J Comput Assist Tomogr 23 (1999), 678–683.
20. 20 Riccialdelli, L., Arnaldi, G., Giacchetti, G., et al. Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. Am J Hypertens 14 (2001), 62–65.
21. 21 Chitalia, V.C., Kolhe, N., Kothari, J., Almeida, A.F., Acute renal failure in a renal transplant donor due to primary antiphospholipid syndrome. Am J Nephrol 21 (2001), 55–57.
22. 22 Saji, M., Nakajima, A., Sendo, W., et al. Antiphospholipid syndrome with complete abdominal aorta occlusion and chondritis. Mod Rheumatol 11 (2001), 159–161.
23. 23 Safley, D.M., McCullough, P.A., Antiphospholipid syndrome with renal artery embolism: case report. Rev Cardiovasc Med 3 (2002), 196–201.
24. 24 Asherson, R.A., Buchanan, N., Baguley, E., Hughes, G.R., Postpartum bilateral renal vein thrombosis in the primary antiphospholipid syndrome. J Rheumatol 20 (1993), 874–876.
25. 25 Morgan, R.J., Feneley, R.C., Renal vein thrombosis caused by primary antiphospholipid syndrome. Br J Urol 74 (1994), 807–808.
26. 26 Sá, H., Freitas, L., Mota, A., et al. Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Clin Nephrol 52 (1999), 56–60.
27. 27 Ko, W.S., Lim, P.S., Sung, Y.P., Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome. Nephrol Dial Transplant 10 (1995), 1929–1931.
28. 28 Lai, N.S., Lan, J.L., Renal vein thrombosis in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 56 (1997), 562–564.
29. 29 Cervera, R., Serrano, R., Pons-Estel, G.J., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018.
30. 30 Zenone, T., Knefati, Y., [Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al]. Rev Med Interne 32 (2011), 261–262.
31. 31 Vaidya, S., Wang, C.C., Gugliuzza, C., Fish, J.C., Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 12 (1998), 439–444.
32. 32 Stone, J.H., Amend, W.J., Criswell, L.A., Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 34 (1999), 1040–1047.
33. 33 Vaidya, S., Gugliuzza, K., Daller, J.A., Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 77 (2004), 1046–1049.
34. 34 Canaud, G., Bienaime, F., Noel, L.H., et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 10 (2010), 2051–2060.
35. 35 Meroni, P.L., Chighizola, C.B., Rovelli, F., Gerosa, M., Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther, 16, 2014, 209.
36. 36 Pierangeli, S.S., Harris, E.N., In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 5 (1996), 451–455.
37. 37 Jankowski, M., Vreys, I., Wittevrongel, C., et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 101 (2003), 157–162.
38. 38 Ramesh, S., Morrell, C.N., Tarango, C., et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest 121 (2011), 120–131.
39. 39 Arad, A., Proulle, V., Furie, R.A., et al. beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 117 (2011), 3453–3459.
40. 40 Raschi, E., Chighizola, C.B., Grossi, C., et al. beta2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 55 (2014), 42–50.
41. 41 Krone, K.A., Allen, K.L., McCrae, K.R., Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 12 (2010), 53–57.
42. 42 Arachchillage, D.R., Efthymiou, M., Mackie, I.J., et al. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost 12 (2014), 1801–1809.
43. 43 Brandt, K.J., Kruithof, E.K., de Moerloose, P., Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 132 (2013), 408–413.
44. 44 Chamley, L.W., McKay, E.J., Pattison, N.S., Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb Res 71 (1993), 103–111.
45. 45 Hwang, K.K., Grossman, J.M., Visvanathan, S., et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 167 (2001), 7192–7198.
46. 46 Abdel-Rahman, M.H., Yang, Y., Zhou, X.P., et al. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 24 (2006), 288–295.
47. 47 Yang, Y.H., Chien, D., Wu, M., et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 182 (2009), 1674–1680.
48. 48 de Laat, B., Wu, X.X., van Lummel, M., et al. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109 (2007), 1490–1494.
49. 49 Yang, C.D., Chen, S.L., Shen, N., et al. Detection of anti-recombinant beta 2-glycoprotein 1 and anti-recombinant beta 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 18 (1998), 5–10.
50. 50 Igarashi, M., Matsuura, E., Igarashi, Y., et al. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 87 (1996), 3262–3270.
51. 51 Iverson, G.M., Victoria, E.J., Marquis, D.M., Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 95 (1998), 15542–15546.
52. 52 Iverson, G.M., Reddel, S., Victoria, E.J., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 169 (2002), 7097–7103.
53. 53 de Laat, B., Derksen, R.H., van Lummel, M., et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 107 (2006), 1916–1924.
54. 54 Satta, N., Kruithof, E.K., Fickentscher, C., et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 117 (2011), 5523–5531.
55. 55 Sorice, M., Longo, A., Capozzi, A., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 56 (2007), 2687–2697.
56. 56 Shi, T., Giannakopoulos, B., Yan, X., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 54 (2006), 2558–2567.
57. 57 Robbins, D.L., Leung, S., Miller-Blair, D.J., Ziboh, V., Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 25 (1998), 51–56.
58. 58 Holers, V.M., Girardi, G., Mo, L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195 (2002), 211–220.
59. 59 Girardi, G., Berman, J., Redecha, P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003), 1644–1654.
60. 60 Girardi, G., Redecha, P., Salmon, J.E., Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 (2004), 1222–1226.
61. 61 Pierangeli, S.S., Girardi, G., Vega-Ostertag, M., et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52 (2005), 2120–2124.
62. 62 Romay-Penabad, Z., Liu, X.X., Montiel-Manzano, G., et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 1108 (2007), 554–566.
63. 63 Rysava, R., Zabka, J., Peregrin, J.H., et al. Acute renal failure due to bilateral renal artery thrombosis associated with primary antiphospholipid syndrome. Nephrol Dial Transplant 13 (1998), 2645–2647.
64. 64 Boltin, D., Boguslavski, V., Sagi, L., et al. Antiphospholipid syndrome presenting as unilateral renal artery occlusion: case report and literature review. Rheumatol Int 29 (2009), 831–835.
65. 65 Sa, H., Freitas, L., Mota, A., et al. Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Clin Nephrol 52 (1999), 56–60.
66. 66 Wilson, W.A., Gharavi, A.E., Koike, T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999), 1309–1311.
67. 67 Erkan, D., Aguiar, C.L., Andrade, D., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696.
68. 68 Cohen, H., Dore, C.J., Clawson, S., et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 24 (2015), 1087–1094.
69. 69 Edwards, M.H., Pierangeli, S., Liu, X., et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (1997), 4380–4384.
70. 70 Sinico, R.A., Cavazzana, I., Nuzzo, M., et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 5 (2010), 1211–1217.
71. 71 Peleg, H., Bursztyn, M., Hiller, N., Hershcovici, T., Renal artery stenosis with significant proteinuria may be reversed after nephrectomy or revascularization in patients with the antiphospholipid antibody syndrome: a case series and review of the literature. Rheumatol Int 32 (2012), 85–90.
72. 72 Fakhouri, F., Noel, L.H., Zuber, J., et al. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 41 (2003), 1205–1211.
73. 73 Henning, B.F., Grone, H.J., Tepel, M., et al. A rare cause of pulmonary-renal syndrome. Nephron 91 (2002), 516–520.
74. 74 Rodriguez-Pinto, I., Espinosa, G., Cervera, R., Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep, 17, 2015, 482.
75. 75 Cervera, R., Rodriguez-Pinto, I., Espinosa, G., on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome. Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23 (2014), 1283–1285.
76. 76 Vellanki, V.S., Parvathina, S., Gondi, S., et al. Post-partum bilateral renal cortical necrosis in antiphospholipid syndrome and systemic lupus erythematosus. Saudi J Kidney Dis Transpl 24 (2013), 549–552.
77. 77 Cervera, R., Tektonidou, M.G., Espinosa, G., et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 20 (2011), 165–173.
78. 78 Silvarino, R., Sant, F., Espinosa, G., et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 20 (2011), 721–729.
79. 79 Gerhardsson, J., Sundelin, B., Zickert, A., et al. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther, 17, 2015, 109.
80. 80 Miranda, J.M., Jara, L.J., Calleja, C., et al. Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE). Reumatol Clin 5 (2009), 209–213.
81. 81 Lanir, N., Zilberman, M., Yron, I., et al. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. J Lab Clin Med 131 (1998), 548–556.
82. 82 Seshan, S.V., Franzke, C.W., Redecha, P., et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114 (2009), 1675–1683.
83. 83 Shapira, I., Andrade, D., Allen, S.L., Salmon, J.E., Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64 (2012), 2719–2723.
84. 84 Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364 (2011), 2561–2563.
85. 85 Noris, M., Mescia, F., Remuzzi, G., STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8 (2012), 622–633.
86. 86 Lonze, B.E., Singer, A.L., Montgomery, R.A., Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362 (2010), 1744–1745.
87. 87 Vivarelli, M., Pasini, A., Emma, F., Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366 (2012), 1163–1165.
88. 88 Herlitz, L.C., Bomback, A.S., Markowitz, G.S., et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23 (2012), 1229–1237.
89. 89 Long, B.R., Leya, F., The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am 22 (2008), 79–94 vi–vii.
90. 90 Alarcon-Segovia, D., Cardiel, M.H., Reyes, E., Antiphospholipid arterial vasculopathy. J Rheumatol 16 (1989), 762–767.
91. 91 Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129 (2007), 1261–1274.
92. 92 Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
93. 93 Gallo, R., Padurean, A., Jayaraman, T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 (1999), 2164–2170.
94. 94 Legendre, C., Sberro-Soussan, R., Zuber, J., et al. Eculizumab in renal transplantation. Transplant Rev (Orlando) 27 (2013), 90–92.
95. 95 Lepin, E.J., Zhang, Q., Zhang, X., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 6 (2006), 1560–1571.
96. 96 Sousa, J.E., Costa, M.A., Abizaid, A.C., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104 (2001), 2007–2011.
97. 97 Finn, A.V., Oh, J.S., Hendricks, M., et al. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. Am Heart J 157 (2009), 383.e1–383.e8.
98. 98 Canaud, G., Legendre, C., Terzi, F., AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. Lupus 24 (2015), 227–230.
99. 99 Erre, G.L., Bosincu, L., Faedda, R., et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int 34 (2014), 535–541.
100. 100 Forman, J.P., Lin, J., Pascual, M., et al. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 4 (2004), 1786–1791.
101. 101 Hadhri, S., Rejeb, M.B., Belarbia, A., et al. Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-beta2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. Thromb Res 131 (2013), e202–e209.
102. 102 Serrano, A., Garcia, F., Serrano, M., et al. IgA antibodies against beta2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int 81 (2012), 1239–1244.
103. 103 Morales, J.M., Martinez-Flores, J.A., Serrano, M., et al. Association of early kidney allograft failure with preformed IgA antibodies to beta2-glycoprotein I. J Am Soc Nephrol 26 (2015), 735–745.
104. 104 Morales, J.M., Serrano, M., Martinez-Flores, J.A., et al. The presence of pretransplant antiphospholipid antibodies IgA anti-beta-2-glycoprotein I as a predictor of graft thrombosis after renal transplantation. [e-pub ahead of print] Transplantation, 2016, 10.1097/TP.0000000000001199 Accessed May 31, 2016.
105. 105 Warner, L.M., Adams, L.M., Sehgal, S.N., Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 37 (1994), 289–297.
106. 106 Fernandez, D., Bonilla, E., Mirza, N., et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 54 (2006), 2983–2988.
107. 107 Kshirsagar, S., Riedl, M., Billing, H., et al. AKT-dependent enhanced migratory capacity of Th17 cells from children with lupus nephritis. J Immunol 193 (2014), 4895–4903.
108. 108 Alperovich, G., Rama, I., Lloberas, N., et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16 (2007), 18–24.
109. 109 Lui, S.L., Tsang, R., Chan, K.W., et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol Dial Transplant 23 (2008), 2768–2776.
110. 110 Letavernier, E., Bruneval, P., Vandermeersch, S., et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24 (2009), 630–638.
111. 111 Canaud, G., Bienaime, F., Viau, A., et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 19 (2013), 1288–1296.
112. 112 Ruffatti, A., Marson, P., Pengo, V., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6 (2007), 196–202.
113. 113 Asherson, R.A., Noble, G.E., Hughes, G.R., Hypertension, renal artery stenosis and the “primary” antiphospholipid syndrome. J Rheumatol 18 (1991), 1413–1415.
114. 114 Nzerue, C.M., Hewan-Lowe, K., Pierangeli, S., Harris, E.N., “Black swan in the kidney”: renal involvement in the antiphospholipid antibody syndrome. Kidney Int 62 (2002), 733–744.
115. 115 Sangle, S.R., D'Cruz, D.P., Abbs, I.C., et al. Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology (Oxford) 44 (2005), 372–377.
116. 116 Sangle, S.R., D'Cruz, D.P., Jan, W., et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 62 (2003), 999–1002.
117. 117 Rollino, C., Boero, R., Elia, F., et al. Antiphospholipid antibodies and hypertension. Lupus 13 (2004), 769–772.
118. 118 Remondino, A., Rosenblatt-Velin, N., Montessuit, C., et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 32 (2000), 2025–2034.
119. 119 Ben-Ami, D., Bar-Meir, E., Shoenfeld, Y., Stenosis in antiphospholipid syndrome: a new finding with clinical implications. Lupus 15 (2006), 466–472.
120. 120 Salaun, E., Bartoli, M.A., Soler, R., et al. Severe symptomatic stenosis of visceral and renal arteries leading primary antiphospholipid syndrome diagnosis. Ann Vasc Surg 28 (2014), 1796.e9–1796.e13.
121. 121 Yildiz, B., Cetin, N., Kural, N., et al. Co-existence of renovascular hypertension, polyarteritis nodosa, antiphospholipid syndrome and methylenetetrahydrofolate reductase mutation. Pediatr Int 55 (2013), e107–e110.
122. 122 Serino, R., Osajima, A., Hiroshige, K., et al. [Renovascular hypertension associated with antiphospholipid antibodies in a woman with systemic lupus erythematosus]. Nihon Jinzo Gakkai Shi 38 (1996), 417–422.
123. 123 Linhartova, K., Slechtova, J., Simon, J., [Antiphospholipid syndrome and vascular disease]. Cas Lek Cesk 138 (1999), 276–279.
124. 124 Aizawa, K., Nakamura, T., Sumino, H., et al. Renovascular hypertension observed in a patient with antiphospholipid-antibody syndrome. Jpn Circ J 64 (2000), 541–543.
125. 125 Kurtulmus, N., Cikrikcioglu, M.A., Aksoy, O., Tukek, T., Primary antiphospholipid syndrome presenting as hyponatremic hypertensive syndrome and acute adrenal insufficiency following it: a rare case. Rheumatol Int 30 (2009), 259–263.